Sign in or Register   Sign in or Register
  |  

Mouse Anti-NF2 Recombinant Antibody (CBWJN-0649) (CBMAB-N2136-WJ)

This product is a Mouse antibody that recognizes NF2. The antibody CBWJN-0649 can be used for immunoassay techniques such as: WB, FC, ICC.
See all NF2 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBWJN-0649
Application
WB, FC, ICC

Basic Information

Specificity
Human
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Neurofibromin 2
Introduction
This gene encodes a protein that is similar to some members of the ERM (ezrin, radixin, moesin) family of proteins that are thought to link cytoskeletal components with proteins in the cell membrane. This gene product has been shown to interact with cell-surface proteins, proteins involved in cytoskeletal dynamics and proteins involved in regulating ion transport. This gene is expressed at high levels during embryonic development; in adults, significant expression is found in Schwann cells, meningeal cells, lens and nerve. Mutations in this gene are associated with neurofibromatosis type II which is characterized by nervous system and skin tumors and ocular abnormalities. Two predominant isoforms and a number of minor isoforms are produced by alternatively spliced transcripts. [provided by RefSeq, Jul 2008]
Entrez Gene ID
4771
UniProt ID
P35240
Alternative Names
Neurofibromin 2; Schwannomin; Neurofibromin 2 (Bilateral Acoustic Neuroma); Moesin-Ezrin-Radixin-Like Protein; Moesin-Ezrin-Radixin Like; Schwannomerlin; SCH;
Function
Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex.
Biological Process
Actin cytoskeleton organization Source: HGNC-UCL
Cell-cell junction organization Source: Ensembl
Ectoderm development Source: Ensembl
Hippocampus development Source: Ensembl
Lens fiber cell differentiation Source: Ensembl
Mesoderm formation Source: Ensembl
Negative regulation of cell-cell adhesion Source: HGNC-UCL
Negative regulation of cell-matrix adhesion Source: HGNC-UCL
Negative regulation of cell migration Source: HGNC-UCL
Negative regulation of cell population proliferation Source: UniProtKB
Negative regulation of MAPK cascade Source: Ensembl
Negative regulation of protein kinase activity Source: Ensembl
Negative regulation of receptor signaling pathway via JAK-STAT Source: HGNC-UCL
Negative regulation of tyrosine phosphorylation of STAT protein Source: HGNC-UCL
Odontogenesis of dentin-containing tooth Source: Ensembl
Positive regulation of cell differentiation Source: Ensembl
Positive regulation of stress fiber assembly Source: HGNC-UCL
Regulation of apoptotic process Source: UniProtKB
Regulation of cell cycle Source: UniProtKB
Regulation of gliogenesis Source: GO_Central
Regulation of hippo signaling Source: UniProtKB
Regulation of neural precursor cell proliferation Source: Ensembl
Regulation of protein localization to nucleus Source: Ensembl
Regulation of protein stability Source: Ensembl
Regulation of stem cell proliferation Source: Ensembl
Schwann cell proliferation Source: HGNC-UCL
Cellular Location
Isoform 1:
Nucleus
Plasma membrane
filopodium membrane
ruffle membrane
Note: In a fibroblastic cell line, isoform 1 is found homogeneously distributed over the entire cell, with a particularly strong staining in ruffling membranes and filopodia. Colocalizes with MPP1 in non-myelin-forming Schwann cells. Binds with DCAF1 in the nucleus. The intramolecular association of the FERM domain with the C-terminal tail promotes nuclear accumulation. The unphosphorylated form accumulates predominantly in the nucleus while the phosphorylated form is largely confined to the non-nuclear fractions.
Isoform 7:
Other locations
perinuclear region
Cytoplasmic granule
Note: Observed in cytoplasmic granules concentrated in a perinuclear location. Isoform 7 is absent from ruffling membranes and filopodia.
Isoform 9:
Other locations
perinuclear region
Cytoplasmic granule
Note: Observed in cytoplasmic granules concentrated in a perinuclear location. Isoform 9 is absent from ruffling membranes and filopodia.
Isoform 10:
Nucleus
Plasma membrane
filopodium membrane
ruffle membrane
Cytoskeleton
Other locations
perinuclear region
Cytoplasmic granule
Note: In a fibroblastic cell line, isoform 10 is found homogeneously distributed over the entire cell, with a particularly strong staining in ruffling membranes and filopodia.
Involvement in disease
Neurofibromatosis 2 (NF2):
Genetic disorder characterized by bilateral vestibular schwannomas (formerly called acoustic neuromas), schwannomas of other cranial and peripheral nerves, meningiomas, and ependymomas. It is inherited in an autosomal dominant fashion with full penetrance. Affected individuals generally develop symptoms of eighth-nerve dysfunction in early adulthood, including deafness and balance disorder. Although the tumors of NF2 are histologically benign, their anatomic location makes management difficult, and patients suffer great morbidity and mortality.
Schwannomatosis 1 (SWNTS1):
A cancer syndrome in which patients develop multiple non-vestibular schwannomas, benign neoplasms that arise from Schwann cells of the cranial, peripheral, and autonomic nerves.
Mesothelioma, malignant (MESOM):
An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.
PTM
Phosphorylation of Ser-518 inhibits nuclear localization by disrupting the intramolecular association of the FERM domain with the C-terminal tail (PubMed:20178741). The dephosphorylation of Ser-518 favors the interaction with NOP53 (PubMed:21167305).
Ubiquitinated by the CUL4A-RBX1-DDB1-DCAF1/VprBP E3 ubiquitin-protein ligase complex for ubiquitination and subsequent proteasome-dependent degradation.

Hiruta, R., Saito, K., Bakhit, M., & Fujii, M. (2023). Current progress in genomics and targeted therapies for neurofibromatosis type 2. Fukushima Journal of Medical Science, 69(2), 95-103.

Ghalavand, M. A., Asghari, A., Farhadi, M., Taghizadeh-Hesary, F., Garshasbi, M., & Falah, M. (2023). The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell International, 23(1), 1-27.

Bachir, S., Shah, S., Shapiro, S., Koehler, A., Mahammedi, A., Samy, R. N., ... & Sengupta, S. (2021). Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. International journal of molecular sciences, 22(2), 690.

Tamura, R. (2021). Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. International journal of molecular sciences, 22(11), 5850.

Coy, S., Rashid, R., Stemmer-Rachamimov, A., & Santagata, S. (2020). An update on the CNS manifestations of neurofibromatosis type 2. Acta neuropathologica, 139, 643-665.

Evans, D. G., King, A. T., Bowers, N. L., Tobi, S., Wallace, A. J., Perry, M., ... & English Specialist NF2 Research Group. (2019). Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genetics in Medicine, 21(7), 1525-1533.

Lee, S., Karas, P. J., Hadley, C. C., Bayley V, J. C., Khan, A. B., Jalali, A., ... & Patel, A. J. (2019). The role of merlin/NF2 loss in meningioma biology. Cancers, 11(11), 1633.

Shen, Y. C., Arellano-Garcia, C., Menjivar, R. E., Jewett, E. M., Dohle, W., Karchugina, S., ... & Barald, K. F. (2019). Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2). BMC Pharmacology and Toxicology, 20(1), 1-13.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-NF2 Recombinant Antibody (CBWJN-0649)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare